Skip to content
HowShorted

BIOCRYST PHARMACEUTICALS INC short interest in 2022

In 2022, BIOCRYST PHARMACEUTICALS INC's disclosed short interest ran from 14.15% of shares outstanding on 14 Jan 2022 to 14.61% on 30 Dec 2022, a change of +0.46 percentage points. The year's high was 16.95% on 15 Jul 2022 and its low 13.55% on 31 Jan 2022, averaging 15.16% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.94 days on 29 Jul 2022. Full history: BIOCRYST PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for BIOCRYST PHARMACEUTICALS INC in 2022

2022 in figures

Start of year
14.15% (14 Jan 2022)
End of year
14.61% (30 Dec 2022)
Change
+0.46 pp
High
16.95% (15 Jul 2022)
Low
13.55% (31 Jan 2022)
Average
15.16%
Highest days to cover
15.94 (29 Jul 2022)
SEC filings marked
9

Every report in 2022

BIOCRYST PHARMACEUTICALS INC short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202214.15%3.54results (8-K)
31 Jan 202213.55%6.74
15 Feb 202213.98%8.45
28 Feb 202214.35%6.28results (8-K), 10-K filed
15 Mar 202214.64%8.81
31 Mar 202213.85%8.38
14 Apr 202215.46%3.20
29 Apr 202216.54%5.97
13 May 202215.98%4.95results (8-K), 10-Q filed
31 May 202215.92%9.79
15 Jun 202216.00%10.63
30 Jun 202216.86%7.42
15 Jul 202216.95%10.34
29 Jul 202215.96%15.94
15 Aug 202214.71%7.04results (8-K), 10-Q filed
31 Aug 202215.01%14.85
15 Sep 202215.50%11.72
30 Sep 202215.13%12.03
14 Oct 202215.21%11.49
31 Oct 202214.82%10.17
15 Nov 202214.95%7.19results (8-K), 10-Q filed
30 Nov 202214.81%15.47
15 Dec 202214.85%10.54
30 Dec 202214.61%10.54

See also: BIOCRYST PHARMACEUTICALS INC's full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.